Matthew 28:8

Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma

Retrieved on: 
Tuesday, April 5, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Cancer, Esophageal cancer, Adenocarcinoma, LinkedIn, Diagnosis, Agilent Technologies, CE, Death, ESCC, Mortality, NYSE, IHC, Survival, Neoplasm, Incidence, Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries, Marie Cassidy, Histology, Quality of life, Lead, Software, Twitter, Hope, Matthew 28:8, Squamous cell carcinoma, Union, Solution, Nivolumab, Fluoropyrimidine, News, Bristol Myers Squibb, PD-L1, Patient, Ipilimumab, Pharmaceutical industry, Facebook

The two most common types of esophageal cancer are squamous cell carcinoma and adenocarcinoma, which account for approximately 85% and 15% of all esophageal cancers, respectively, though esophageal tumor histology can vary by region and country.

Key Points: 
  • The two most common types of esophageal cancer are squamous cell carcinoma and adenocarcinoma, which account for approximately 85% and 15% of all esophageal cancers, respectively, though esophageal tumor histology can vary by region and country.
  • PD-L1 is a critical biomarker for response to anti-PD-1 therapies, including the immunotherapeutic agent OPDIVO based on the Phase 3 CheckMate-648 trial results.
  • We greatly value our relationship with Bristol Myers Squibb, and are committed to continuing developing and commercializing market-leading companion diagnostic products.
  • Agilent is the worldwide leader in partnering with pharmaceutical companies to develop IHC-based diagnostics for targeted cancer therapy.

Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC)

Retrieved on: 
Tuesday, April 5, 2022
Software, Networks, Internet, Hardware, Pharmaceutical, Electronic Design Automation, Data Management, Oncology, Consumer Electronics, Technology, Biotechnology, Health, Telecommunications, Risk, Recurrence, LinkedIn, Diagnosis, Agilent Technologies, NYSE, Cancer, Death, Marie Cassidy, Quality of life, Software, Squamous cell carcinoma, Transitional cell carcinoma, Twitter, Hope, Matthew 28:8, Physician, Union, Nivolumab, Solution, News, Bristol Myers Squibb, PD-L1, Transitional epithelium, Patient, Disease, Palladium, EU, Facebook

The expanded use of PD-L1 IHC 28-8 pharmDx helps physicians in the EU identify MIUC patients for adjuvant treatment with OPDIVO.

Key Points: 
  • The expanded use of PD-L1 IHC 28-8 pharmDx helps physicians in the EU identify MIUC patients for adjuvant treatment with OPDIVO.
  • Agilent supports pathologists with products that provide accuracy and reliability in PD-L1 testing, said Sam Raha, president of Agilent's Diagnostics and Genomics Group.
  • We are pleased that this now includes the treatment of MIUC for adjuvant treatment with OPDIVO.
  • Managing noninvasive recurrences after definitive treatment for muscle-invasive bladder cancer or high-grade upper tract urothelial carcinoma.

Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Retrieved on: 
Thursday, October 21, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Death, Cancer, Agilent Technologies, Matthew 28:8, LinkedIn, PD, Neoplasm, IHC, NGS, Twitter, Patient, NYSE, PD-L1, Esophageal cancer, Adult, Nivolumab, PFS, News, Mortality, CPS, Incidence, Physician, Progression-free survival, Pharmaceutical industry

Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers.
  • 1 Together with cancers of the gastroesophageal junction, they constitute an important and growing global health concern.
  • PD-L1 is a critical biomarker for response to anti-PD-1 therapies, including the immunotherapeutic agent OPDIVO (nivolumab).
  • CA: A Cancer Journal for Clinicians, 71(3), 209249. https://doi.org/10.3322/caac.21660
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005619/en/